NCT05110196 2025-12-03
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
Novartis
Phase 4 Completed
Clinical Trials
17 trialsNCT04677595 2025-06-24
GeoMETry-C
Novartis
Phase 2 Completed
NCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02414139 2024-03-20
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT02386826 2023-09-21
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1 Completed
NCT02795429 2023-07-03
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Novartis
Phase 1/2 Completed
NCT02019693 2023-03-21
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02750215 2022-03-14
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Massachusetts General Hospital
Phase 2 Completed
NCT03647488 2022-01-24
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT01911507 2021-10-13
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
NCT01546428 2020-12-19
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02474537 2020-12-10
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Novartis
Phase 1 Completed
NCT02520752 2020-12-10
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02626234 2020-12-10
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01072266 2017-11-22
A Dose-escalation Study in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1 Completed